This primer addresses common questions, concerns, and misconceptions surrounding the Priority Review Voucher Program. It provides evidence-based responses and policy context explaining how the program supports rare disease drug development and patient access to therapies.
New Name, Same Commitment to Rare Diseases
The EveryLife Foundation for Rare Diseases has become The RARE Foundation! Read more about our new brand and how it unifies our advocacy work on behalf of the rare disease community.
